New preclinical data for assembly biosciences' oral hepatitis d virus entry inhibitor abi-6250 and next-generation hepatitis b virus capsid assembly modulator abi-4334 presented at the easl congress 2025

– late-breaker poster highlights preclinical profile of abi-6250, currently in phase 1a with data anticipated in q3 2025 – – second poster describes in vitro studies of effects on viral infection markers by abi-4334, currently in phase 1b with data anticipated in the first half of 2025 – south san francisco, calif., may 07, 2025 (globe newswire) -- assembly biosciences, inc. (nasdaq: asmb), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced new preclinical and in vitro data for two therapeutic candidates featured in poster presentations, including one late-breaker, at the european association for the study of the liver (easl) congress, taking place may 7-10, 2025, in amsterdam, the netherlands.
ASMB Ratings Summary
ASMB Quant Ranking